A R Kagan

Summary

Affiliation: Kaiser Permanente
Country: USA

Publications

  1. ncbi Communicating with patients
    A Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles, California 90027, USA
    Am J Clin Oncol 27:547-9. 2004
  2. ncbi The impact (?) of fine arts on the art of medicine
    Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles, California 90027, USA
    Am J Clin Oncol 28:100-1. 2005
  3. ncbi Intensity-modulated radiotherapy for adenocarcinoma of the prostate: a point of view
    A Robert Kagan
    Department of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, CA 90027, USA
    Int J Radiat Oncol Biol Phys 62:454-9. 2005
  4. ncbi Statistics is not a surrogate for judgment
    A Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles, California 90027, USA
    Am J Clin Oncol 28:327-8. 2005
  5. ncbi Cancer management controversy: on residency training
    A Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Center, Los Angeles, California 90027, USA
    Am J Clin Oncol 27:106-7. 2004
  6. ncbi The case for case reports: avoiding statistical seduction
    A Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles, CA, USA
    Am J Clin Oncol 29:325-7. 2006
  7. ncbi Are we ducking the issues of aging?
    A Robert Kagan
    Southern California Kaiser Permanente, Department of Radiation Oncology, Los Angeles, CA 90027, USA
    Am J Clin Oncol 29:514-6. 2006
  8. ncbi The lost connection: the patient-doctor relationship
    A Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles, CA 90027, USA
    Am J Clin Oncol 30:325-6. 2007
  9. ncbi Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes
    T Do
    Department of Radiation Oncology, UCLA Medical Center, Los Angeles, CA, USA
    Int J Radiat Oncol Biol Phys 50:1220-5. 2001
  10. ncbi Prostate-specific antigen-all that rises is not refractory
    B L Hintz
    Department of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, California, USA
    Urology 57:975. 2001

Collaborators

  • R J Schulz
  • Robert Kagan
  • B L Hintz
  • T Do
  • T M Do
  • Richard Steckel
  • G Dave
  • R G Parker
  • R Parker
  • R B Smith
  • A Van Nieuwenhuize

Detail Information

Publications27

  1. ncbi Communicating with patients
    A Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles, California 90027, USA
    Am J Clin Oncol 27:547-9. 2004
    ..The responsibility for this communication is the doctor's. Herein is an examination of some of the major areas of contention that, if acknowledged by the physician, can lead to better communication with the patient...
  2. ncbi The impact (?) of fine arts on the art of medicine
    Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles, California 90027, USA
    Am J Clin Oncol 28:100-1. 2005
  3. ncbi Intensity-modulated radiotherapy for adenocarcinoma of the prostate: a point of view
    A Robert Kagan
    Department of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, CA 90027, USA
    Int J Radiat Oncol Biol Phys 62:454-9. 2005
    ....
  4. ncbi Statistics is not a surrogate for judgment
    A Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles, California 90027, USA
    Am J Clin Oncol 28:327-8. 2005
  5. ncbi Cancer management controversy: on residency training
    A Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Center, Los Angeles, California 90027, USA
    Am J Clin Oncol 27:106-7. 2004
  6. ncbi The case for case reports: avoiding statistical seduction
    A Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles, CA, USA
    Am J Clin Oncol 29:325-7. 2006
    ....
  7. ncbi Are we ducking the issues of aging?
    A Robert Kagan
    Southern California Kaiser Permanente, Department of Radiation Oncology, Los Angeles, CA 90027, USA
    Am J Clin Oncol 29:514-6. 2006
  8. ncbi The lost connection: the patient-doctor relationship
    A Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles, CA 90027, USA
    Am J Clin Oncol 30:325-6. 2007
  9. ncbi Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes
    T Do
    Department of Radiation Oncology, UCLA Medical Center, Los Angeles, CA, USA
    Int J Radiat Oncol Biol Phys 50:1220-5. 2001
    ..CONCLUSION: Evaluation of serum PSA level at 45 Gy of salvage radiotherapy for biochemical relapses after prostatectomy may serve as a significant prognosticator for both biochemical and clinical disease-free outcomes...
  10. ncbi Prostate-specific antigen-all that rises is not refractory
    B L Hintz
    Department of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, California, USA
    Urology 57:975. 2001
    ..We report a patient with a rising PSA level and elevated testosterone level after depot leuprolide in whom the PSA level subsequently declined with administration of bicalutamide...
  11. ncbi High-grade carcinoma of the prostate: a comparison of current local therapies
    T M Do
    Department of Radiation Oncology, Kaiser Permanente Medical Center, Los Angeles, California 90027, USA
    Urology 57:1121-6; discussion 1126-7. 2001
    ..The addition of postoperative radiotherapy in the treatment of these patients may be associated with improved biochemical and clinical PFS compared with either modality alone...
  12. ncbi Psychologically high-risk patients in a radiation oncology department
    A Robert Kagan
    Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles, California 90027, U.S.A
    Am J Clin Oncol 25:425-7. 2002
  13. ncbi Commentary on IMRT and cancer of the prostate. Intensity-modulated radiation therapy
    R J Schulz
    Int J Radiat Oncol Biol Phys 55:851-2; author reply 852-3. 2003
  14. ncbi Commentary on dose escalation and biochemical failure in prostate cancer: in regard to Eade et al. (Int. J. Radiat. Oncol. Biol. Phys. 2007;68:682-689)
    Robert J Schulz
    Int J Radiat Oncol Biol Phys 70:645; author reply 645-6. 2008
  15. ncbi Healthcare for terminal cancer patients
    A Robert Kagan
    Int J Radiat Oncol Biol Phys 62:1261-3. 2005
  16. ncbi The multidisciplinary clinic
    A Robert Kagan
    Int J Radiat Oncol Biol Phys 61:967-8. 2005
  17. ncbi Some comments and data on the overtreatment of prostate cancer
    R J Schulz
    Int J Radiat Oncol Biol Phys 60:690-1. 2004
  18. ncbi In regard to "research in medical physics," IJROBP 49:891-895; 2001
    R J Schulz
    Int J Radiat Oncol Biol Phys 52:274-5. 2002
  19. ncbi On the role of intensity-modulated radiation therapy in radiation oncology
    R J Schulz
    Department of Therapeutic Radiology, Yale University, Johnson, Vermont 05656, UDA
    Med Phys 29:1473-82. 2002
    ..By providing this modicum of perspective, physicists will be in a better position to evaluate these new technologies in more fundamental clinical terms, and thereby enhance their contributions to the overall care of the cancer patient...
  20. ncbi A commentary on dose escalation and bNED in prostate cancer
    A Robert Kagan
    Int J Radiat Oncol Biol Phys 55:1151; author reply 1151-2. 2003
  21. ncbi More precisely defined dose distributions are unlikely to affect cancer mortality
    R J Schulz
    Med Phys 30:276. 2003
  22. ncbi New technology in radiation oncology
    R J Schulz
    Oncology (Williston Park) 18:249, 253; author reply 253-4. 2004
  23. ncbi Informed consent
    A Robert Kagan
    Int J Radiat Oncol Biol Phys 59:634-6. 2004
  24. ncbi Evidence-based oncology
    A Robert Kagan
    Cancer Invest 22:321-3. 2004
  25. ncbi Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization
    Robert J Schulz
    Cancer 101:208-9; author reply 209-10. 2004
  26. ncbi Biochemical recurrence-free survival: does it relate to survival?
    R J Schulz
    Int J Radiat Oncol Biol Phys 59:1261; author reply 1261-2. 2004
  27. ncbi Comment on dose escalation and biochemical failure in prostate cancer: in regard to Kuban et al. (Int J Radiat Oncol Biol Phys 2008;70:67-74)
    Robert J Schulz
    Int J Radiat Oncol Biol Phys 71:1288; author reply 1288-9. 2008